NX-RETA-10Planned
Retatrutide
10 mg nominal
GLP-3R (supplier label). White lyophilized powder in a vial. Supplied as a lyophilized powder for laboratory research. Supplier-reported purity: 99.92%.
Open original supplier COA (PDF) ↗Documentation-first research materials
Research
with clarity.
Nexora is building a focused catalog of research materials with transparent identity, lot-specific documentation, and traceability designed into every product.
Seven supplier COAsSupplier reports available; shipment matching pending
Clear identityNominal strength and report-listed identity
Traceable recordsReceived-lot verification before release
Launch catalog
Focused by design.
Seven planned research products with original supplier reports, strength-specific records, and transparent documentation status.
DraftThe seven-product lineup is selected. Original supplier COAs are available below. Inventory availability, exact shipping batches, product identity, and quantity acceptance remain subject to review before ordering opens.
NX-KLOW-80Planned
KLOW
80 mg nominal
GHK-Cu / KPV / Thymosin Beta-4 / BPC-157. White lyophilized powder in a vial. Supplied as a lyophilized blend for laboratory research. Nominal component formulation remains pending confirmation. Supplier-reported purity: 99.93%.
Open original supplier COA (PDF) ↗NX-GHK-50Planned
GHK-Cu
50 mg nominal
GHK-Cu. Blue lyophilized powder in a vial. Supplied as a lyophilized powder for laboratory research. Supplier-reported purity: 99.92%.
Open original supplier COA (PDF) ↗NX-MOTS-10Planned
MOTS-c
10 mg nominal
MOTS-c. White lyophilized powder in a vial. Supplied as a lyophilized powder for laboratory research. Supplier-reported purity: 99.32%.
Open original supplier COA (PDF) ↗NX-KPV-10Planned
KPV
10 mg nominal
KPV. White lyophilized powder in a vial. Supplied as a lyophilized powder for laboratory research. Supplier-reported purity: 99.52%.
Open original supplier COA (PDF) ↗NX-TB5-10Planned
TB-500
10 mg nominal
Thymosin Beta-4 (report identity). White lyophilized powder in a vial. Supplied as a lyophilized powder for laboratory research. Exact supplied identity remains pending confirmation. Supplier-reported purity: 99.50%.
Open original supplier COA (PDF) ↗NX-TESA-10Planned
Tesamorelin
10 mg nominal
Tesamorelin. White lyophilized powder for laboratory research. Supplier-reported purity: 99.49%. Reported mean content: 11.14 mg; quantity acceptance review pending.
Open original supplier COA (PDF) ↗Quality framework
Documentation is part of the product.
Nexora’s release process is being designed around clear records—not vague promises. Products should not be listed for sale until the applicable identity, supplier, lot, and certificate details are reviewed.
Confirm product identity
Verify the compound name, form, labeled strength, and Nexora catalog number before listing.
Review supplier records
Maintain supplier and purchasing documentation that connects inventory to the received lot.
Link the lot and COA
Match the labeled lot to its corresponding certificate and publish the record at a stable URL.
Approve release copy
Check product text for accuracy and keep it free from dosing, treatment, or human-outcome claims.
Original supplier documents
Seven products. Seven reports.
View original laboratory PDFs supplied by Purple Direct. These reports describe the tested samples, not yet Nexora's received inventory.
Report statusReceived October 1 and reported October 3, 2026. Supplier lot fields use cap colors. Matching to a unique shipment batch and acceptance of measured content are pending. Reported purity is separate from vial quantity. Documents have not been independently authenticated by Nexora.
7 supplier reports
Purp2610010632
Retatrutide 10 mg
- Reported purity
- 99.92%
- Reported date
- October 3, 2026
- Laboratory
- Freedom Diagnostics
- Supplier lot field
- Black Cap
Supplier sample report. Nexora shipment-batch match pending.
View original COA (PDF) ↗Purp2610010583
KLOW 80 mg
- Reported purity
- 99.93%
- Reported date
- October 3, 2026
- Laboratory
- Freedom Diagnostics
- Supplier lot field
- Black Cap
Supplier sample report. Nexora shipment-batch match pending.
View original COA (PDF) ↗Purp2610010562
GHK-Cu 50 mg
- Reported purity
- 99.92%
- Reported date
- October 3, 2026
- Laboratory
- Freedom Diagnostics
- Supplier lot field
- Black Cap
Supplier sample report. Nexora shipment-batch match pending.
View original COA (PDF) ↗Purp2610010597
MOTS-c 10 mg
- Reported purity
- 99.32%
- Reported date
- October 3, 2026
- Laboratory
- Freedom Diagnostics
- Supplier lot field
- Yellow Cap
Supplier sample report. Nexora shipment-batch match pending.
View original COA (PDF) ↗Purp2610010590
KPV 10 mg
- Reported purity
- 99.52%
- Reported date
- October 3, 2026
- Laboratory
- Freedom Diagnostics
- Supplier lot field
- Green Cap
Supplier sample report. Nexora shipment-batch match pending.
View original COA (PDF) ↗Purp2610010653
TB-500 10 mg
- Reported purity
- 99.50%
- Reported date
- October 3, 2026
- Laboratory
- Freedom Diagnostics
- Supplier lot field
- White Cap
Supplier sample report. Nexora shipment-batch match pending.
View original COA (PDF) ↗Purp2610010660
Tesamorelin 10 mg
- Reported purity
- 99.49%
- Reported date
- October 3, 2026
- Laboratory
- Freedom Diagnostics
- Supplier lot field
- Black Cap
Supplier sample report. Reported mean content: 11.14 mg. Nexora shipment-batch match and quantity acceptance pending.
View original COA (PDF) ↗PDF links open original supplier documents in a new tab. The Tesamorelin report is an unchanged copy hosted by Nexora. Supplier sign-in may be required. Product report details show the reported net content and identity notes. Supplier documents do not establish suitability for human or veterinary use.
FAQ
Clear answers before launch.
Are Nexora products available to order?
Not yet. This is a preview of the planned catalog and quality system. Checkout will remain disabled until products, documentation, policies, banking, and an approved payment processor are ready.
Are these products intended for personal use?
No. Nexora products are intended solely for laboratory research. They are not for human or veterinary use, and the site will not provide dosing, administration, treatment, or medical guidance.
How will certificates be provided?
Original supplier reports are linked in the COA section and product details. Once inventory is received and reviewed, Nexora will connect the released lot to its matching record. The current supplier sample reports are not yet matched to a Nexora shipment.
Which products are planned for launch?
The planned lineup is Retatrutide 10 mg, KLOW 80 mg, GHK-Cu 50 mg, MOTS-c 10 mg, KPV 10 mg, TB-500 10 mg, and Tesamorelin 10 mg. Release remains pending review of received inventory, batch traceability, identity, and quantity specifications.
Nexora is preparing for launch
Built carefully from the first lot forward.
Register your laboratory research purpose and business type through your research account. Registration records your declaration; it does not independently verify eligibility. Ordering remains closed until customer review, product documentation and payment processing are ready.